Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation

Male Adult Medical Sciences Bioinformatics 610 Transplantation, Autologous Article Biomedical Informatics 0302 clinical medicine Medical Specialties Medicine and Health Sciences Humans RC254-282 Aged Retrospective Studies Transplantation Remission Induction Hematopoietic Stem Cell Transplantation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Middle Aged Treatment Outcome Oncology Female Multiple Myeloma Autologous
DOI: 10.1038/s41408-024-01062-2 Publication Date: 2024-05-17T07:02:53Z
ABSTRACT
AbstractAutologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small proportion achieve a durable response. In this retrospective study we included 1576 patients, 244 (15%) of whom were long-term responders (LTR), defined as having a progression-free survival (PFS) of ≥8 years after transplant. Patients in the LTR group were younger than the non-LTR group (median age 58.4 vs. 59.5 years; p = 0.012), less likely to have high-risk cytogenetics (4% vs. 14%; p < 0.001), more often had <50% bone marrow plasma cells (67% vs. 58%; p = 0.018) and R-ISS stage I disease (43% vs. 34%). More patients in the LTR group received post-transplant maintenance (63% vs. 52%; p = 0.002). Patients in the LTR group had higher rates of complete response (CR) at day100 (41% vs. 27%; p < 0.001) and at best post-transplant response (70% vs. 37%; p < 0.001), compared to the non-LTR group. Patients in the LTR groups had a median PFS of 169.3 months and the median overall survival (OS) had not been reached. The leading cause of death in the LTR was disease progression. In conclusion, 15% of patients in the cohort were LTR after upfront autoHCT, with distinct characteristics and a median PFS of more than 14 years.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (26)
CITATIONS (7)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....